Effect of <italic style="font-style: italic">Shenfu Injection </italic>（参附注射液） on SIRT1 Deacetylation-modified Regulation of HMGB1/TLR4/NF-κB Pathway in Isoproterenol-induced Cardiomyocyte Injury Model

HUANG Shumin; LIAO Xiaoqian; FAN Xingyu; WANG Ziyi; HU Zhixi

doi:10.13288/j.11-2166/r.2024.14.012

您当前的位置：

首页 >

文章列表页 >

Effect of Shenfu Injection （参附注射液） on SIRT1 Deacetylation-modified Regulation of HMGB1/TLR4/NF-κB Pathway in Isoproterenol-induced Cardiomyocyte Injury Model

更新时间：2024-07-19

- Effect of Shenfu Injection （参附注射液） on SIRT1 Deacetylation-modified Regulation of HMGB1/TLR4/NF-κB Pathway in Isoproterenol-induced Cardiomyocyte Injury Model
- Journal of Traditional Chinese Medicine Vol. 65, Issue 14, Pages: 1488-1495(2024)
- 作者机构：
  
  1.福建中医药大学附属第二人民医院，福建省福州市五四路282号，350003
  2.湖南中医药大学
  3.中国中医科学院广安门医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2024.14.012
  CLC：
- Received：05 March 2024，
  
  Revised：2024-04-25，
  
  Published：17 July 2024
- 稿件说明：
移动端阅览
黄淑敏,廖晓倩,范星宇等.参附注射液对异丙肾上腺素诱导的心肌细胞损伤模型中SIRT1去乙酰化修饰调控HMGB1/TLR4/NF-κB通路的影响[J].中医杂志,2024,65(14):1488-1495.

HUANG Shumin,LIAO Xiaoqian,FAN Xingyu,et al.Effect of Shenfu Injection （参附注射液） on SIRT1 Deacetylation-modified Regulation of HMGB1/TLR4/NF-κB Pathway in Isoproterenol-induced Cardiomyocyte Injury Model[J].Journal of Traditional Chinese Medicine,2024,65(14):1488-1495.
黄淑敏,廖晓倩,范星宇等.参附注射液对异丙肾上腺素诱导的心肌细胞损伤模型中SIRT1去乙酰化修饰调控HMGB1/TLR4/NF-κB通路的影响[J].中医杂志,2024,65(14):1488-1495. DOI： 10.13288/j.11-2166/r.2024.14.012.

HUANG Shumin,LIAO Xiaoqian,FAN Xingyu,et al.Effect of Shenfu Injection （参附注射液） on SIRT1 Deacetylation-modified Regulation of HMGB1/TLR4/NF-κB Pathway in Isoproterenol-induced Cardiomyocyte Injury Model[J].Journal of Traditional Chinese Medicine,2024,65(14):1488-1495. DOI： 10.13288/j.11-2166/r.2024.14.012.

摘要

目的

从沉默信息调节因子1（SIRT1）去乙酰化修饰调控高迁移率族蛋白B1（HMGB1）/Toll样受体4（TLR4）/核因子κB（NF-κB）通路探讨参附注射液对异丙肾上腺素诱导的大鼠心肌细胞损伤的影响及可能作用机制。

方法

通过CCK-8法筛选盐酸异丙肾上腺素最佳干预浓度及干预时间、参附注射液药物最佳干预浓度。取对数生长的H9c2大鼠心肌细胞以5×10

个细胞/孔，分为正常组、模型组、参附注射液组、SIRT1抑制剂组，每组3个复孔。除正常组外其余各组细胞采用盐酸异丙肾上腺素诱导建立慢性心力衰竭细胞模型。造模后参附注射液组再加最佳干预浓度的参附注射液处理，SIRT1抑制剂组造模后加1 μmol/L的SIRT1抑制剂EX-527处理，时间为筛选的最佳干预时间。采用CCK-8法检测各组细胞活性及计算抑制率；ELISA法检测心肌细胞中烟酰胺腺嘌呤二核苷酸氧化态/烟酰胺腺嘌呤二核苷酸还原态（NAD+/NADH）值；免疫荧光法检测心肌细胞HMGB1及SIRT1免疫荧光定位情况；蛋白免疫印迹法检测心肌细胞乙酰化HMGB1蛋白表达，细胞核、细胞质中HMGB1蛋白表达，心肌细胞中SIRT1、TLR4、髓样细胞分化因子88（MYD88）、NF-κB p65蛋白表达；RT-qPCR法检测心肌细胞SIRT1、HMGB1、TLR4、MYD88、NF-κB p65 mRNA表达。

结果

最终选择盐酸异丙肾上腺素最佳干预浓度为300 μmol/L，干预时间为48 h；8%为参附注射液最佳干预浓度。与正常组比较，模型组心肌细胞活性、NAD+/NADH值、细胞核HMGB1蛋白表达、心肌细胞SIRT1蛋白及mRNA表达均降低；细胞抑制率、心肌细胞乙酰化HMGB1蛋白、细胞质HMGB1蛋白表达，心肌细胞TLR4、MYD88、NF-κB p65蛋白及mRNA表达，HMGB1 mRNA表达均升高（

＜0.05）；荧光定位显示，模型组心肌细胞HMGB1含量增加并且定位

在细胞核与细胞质中均有体现。与模型组和SIRT1抑制剂组比较，参附注射液组上述各指标均显著改善（

＜0.05）；荧光定位显示，参附注射液组SIRT1含量增加，HMGB1含量减少并且定位主要在细胞核。

结论

参附注射液可以通过提高SIRT1表达以降低HMGB1乙酰化水平，调控HMGB1/TLR4/NF-κB通路从而抑制HMGB1的核易位达到改善心肌细胞损伤的作用。

Abstract

Objective

To investigate the effect and possible mechanism of

Shenfu Injection

（参附注射液） on rat cardiomyocyte injury induced by isoproterenol from the perspective of regulating the high mobility group protein B1 （HMGB1）/ Toll-like receptor 4 （TLR4）/nuclear factor κB （NF-κB） pathway through the deacetylation modification of silent information regulator 1 （SIRT1）.

Methods

The optimal concentration and intervention duration of isoproterenol hydrochloride and the optimal intervention concentration of

Shenfu Injection

were screened out by CCK-8 method. Logarithmically growing H9c2 rat cardiomyocytes were taken at 5×10

cells/well and divided into normal group， model group，

Shenfu Injection

group， and SIRT1 inhibitor group， with 3 replicates in each group.Except for the normal group， the cells in the other groups were induced by isoproterenol hydrochloride to establish a chronic heart failure cell model. After modeling， the

Shenfu Injection

group was given

Shenfu Injection

at the optimal intervention concentration， and the SIRT1 inhibitor group was given 1 μmol/L of SIRT1 inhibitor EX-527， for optimal intervention duration.CCK-8 assay was used to detect the cell activity and calculate the inhibitory rate. ELISA assay was used to detect the nicotinamide adenine dinucleotide oxidation state/ nicotinamide adenine dinucleotide reduction state （NAD+/NADH） in cardiomyocytes. Immunofluorescence was used to detect the immunofluorescence localization of HMGB1 and SIRT1 in cardiomyocytes. Western blotting was used to detect the protein expression of acetylated HMGB1 in cardiomyocyte

s， HMGB1 in the nucleus and cytoplasm， and SIRT1， TLR4， myeloid differentiation factor 88 （MYD88） and NF-κB p65 in cardiomyocytes. RT-qPCR was used to detect the mRNA expression of SIRT1， HMGB1， TLR4， MYD88 and NF-κB p65 in cardiomyocytes.

Results

The optimal intervention concentration of isoproterenol hydrochloride was 300 μmol/L， and the intervention duration was 48 hours； 8% was the optimal intervention concentration of

Shenfu Injection

. Compared to those in the normal group， the cell activity， NAD+/NADH value， nuclear HMGB1 protein expression， cardiomyocyte SIRT1 protein and mRNA expression in the model group decreased， while the cell inhibition rate， cardiomyocyte acetylated HMGB1 and cytoplasmic HMGB1 protein expression， cardiomyocyte TLR4， MYD88， NF-κB p65 protein and mRNA expression all increased （

＜0.05）； fluorescence localization showed that the content of HMGB1 in cardiomyocytes in the model group increased and was localized in both the nucleus and cytoplasm.Compared to the model group and the SIRT1 inhibitor group， the

Shenfu Injection

group showed significant improvements in all the above indicators （

＜0.05）； fluorescence localization showed that the SIRT1 content increased in the

Shenfu injection

group， while the HMGB1 content decreased， and was mainly located in the nucleus.

Conclusion

Shenfu Injection

can improve myocardial cell damage by increasing SIRT1 expression to reduce the acetylation level of HMGB1， regulating the HMGB1/TLR4/NF-κB pathway and inhibiting the nuclear translocation of HMGB1.

关键词

Keywords

references

邱伯雍，王永霞 . 慢性心力衰竭流行病学及防治研究进展［J］. 中华实用诊断与治疗杂志， 2017 ， 31 （ 6 ）： 619 - 621 .

PELLEGRINI L ， FOGLIO E ， PONTEMEZZO E ， et al . HMGB1 and repair： focus on the heart ［J］. Pharmacol Ther ， 2019 ， 196 ： 160 - 182 . doi： 10.1016/j.pharmthera. 2018.12.005 http://dx.doi.org/10.1016/j.pharmthera.2018.12.005 .

VOLZ HC ， LAOHACHEWIN D ， SCHELLBERG D ， et al . HMGB1 is an independent predictor of death and heart transplantation in heart failure ［J］. Clin Res Cardiol ， 2012 ， 101 （ 6 ）： 427 - 435 .

HAIGIS MC ， SINCLAIR DA . Mammalian sirtuins： biological insights and disease relevance ［J］. Annu Rev Pathol ， 2010 ， 5 ： 253 - 295 . doi： 10.1146/annurev.pathol. 4.110807.092250 http://dx.doi.org/10.1146/annurev.pathol.4.110807.092250 .

KIM YM ， PARK EJ ， KIM JH ， et al . Ethyl pyruvate inhi-bits the acetylation and release of HMGB1 via effects on SIRT1/STAT signaling in LPS-activated RAW264.7 cells and peritoneal macrophages ［J］. Int Immunopharmacol ， 2016 ， 41 ： 98 - 105 . doi： 10.1016/j.intimp.2016.11.002 http://dx.doi.org/10.1016/j.intimp.2016.11.002 .

WANG T ， YANG B ， JI R ， et al . Omega-3 polyunsaturated fatty acids alleviate hepatic steatosis-induced inflammation through Sirt1-mediated nuclear translocation of NF-κB p65 subunit in hepatocytes of large yellow croaker （Larmichthys crocea）［J］. Fish Shellfish Immunol ， 2017 ， 71 ： 76 - 82 . doi： 10.1016/j.fsi.2017.09.064 http://dx.doi.org/10.1016/j.fsi.2017.09.064 .

周亚滨，夏兆晨，张晶晶，等 . 中药注射液治疗心力衰竭疗效研究的网状Meta分析［J］. 中国循证医学杂志， 2021 ， 21 （ 9 ）： 1067 - 1074 .

徐琛，吴志勇，陆寒梅 . 参附注射液治疗心肾阳虚型慢性心衰临床观察［J］. 中国中医药现代远程教育， 2019 ， 17 （ 19 ）： 88 - 90 .

黄淑敏，廖晓倩，范星宇，等 . 基于HMGB1/TLR4/NF-κB信号通路探讨参附注射液对慢性心力衰竭大鼠的保护作用［J］. 中国中药杂志， 2022 ， 47 （ 20 ）： 5556 - 5563 .

杨梦，胡思远，李琳，等 . 基于“以方测证”探讨异丙肾上腺素诱导慢性心衰小鼠模型的中医证型及证候本质［J］. 中药药理与临床， 2024 ， 40 （ 2 ）： 101 - 108 .

PELLICORI P ， KHAN MI ， GRAHAM FJ ， et al . New perspectives and future directions in the treatment of heart failure ［J］. Heart Fail Rev ， 2020 ， 25 （ 1 ）： 147 - 159 .

ZHANG Y ， BAUERSACHS J ， LANGEER HF . Immune mechanisms in heart failure ［J］. Eur J Heart Fail ， 2017 ， 19 （ 11 ）： 1379 - 1389 .

TSUNG A ， KLUNE JR ， ZHANG X ， et al . HMGB1 release induced by liver ischemia nvolves Toll-like receptor 4 dependent reactive oxygen species production and alcium mediated signaling ［J］. Exp Med ， 2007 ， 204 （ 12 ）： 2913 - 2933 ．

GORDON JW ， SHAW JA ， KIRSHENBAUM LA . Multiple facets of NF-κB in the heart： to be or not to NF-κB ［J］. Circ Res ， 2011 ， 108 （ 9 ）： 1122 - 1132 .

FUNAYAMA A ， SHISHIDO T ， NETSU S ， et al . Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure ［J］. Cardiovasc Res ， 2013 ， 99 （ 4 ）： 657 - 664 .

ZAMORA R ， BARCLAY D ， YIN J ， et al . HMGB1 is a central driver of dynamic pro-inflammatory networks in pediatric acute liver failure induced by acetaminophen ［J］. Sci Rep ， 2019 ， 9 （ 1 ）： 5971 .

QI Z ， ZHANG Y ， QI S ， et al . Salidroside inhibits HMGB1 acetylation and release through upregulation of SIRT1 during inflammation ［J］. Oxid Med Cell Longev ， 2017 ， 2017 ： 9821543 . doi： 10.1155/2017/9821543 http://dx.doi.org/10.1155/2017/9821543 .

D'ONOFRIO N ， SERVILLO L ， BALESTRIERI ML . SIRT1 and SIRT6 signaling pathways in cardiovascular disease protection ［J］. Antioxid Redox Signal ， 2018 ， 28 （ 8 ）： 711 - 732 .

JIA Y ， GAO P ， CHEN H ， et al . SIRT1 suppresses PMA and ionomycin-induced ICAM-1 expression in endothelial cells ［J］. Sci China Life Sci ， 2013 ， 56 （ 1 ）： 19 - 25 .

曾德金 . 参附注射液的药理研究及临床应用进展［J］. 中西医结合研究， 2019 ， 11 （ 3 ）： 159 - 161 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Shenqi Jianxin Formula（参芪健心方）on Mitochondrial Autophagy and the PINK1/Parkin Signaling Pathway in Cardiac Tissues in Chronic Heart Failure

Effect of Optimized New Shengmai Powder （优化新生脉散方） on Exercise Tolerance in Patients with Chronic Heart Failure of Qi Deficiency，Blood Stasis and Fluid Retention Syndrome：A Randomized，Double-Blind，Placebo-Controlled Trial

Overview of Study on Syndromic Characteristics and Microscopic Indicators of Qi Deficiency and Blood Stasis Syndrome in Chronic Heart Failure

Bushen Huoxue Formula （补肾活血方） Combined with Conventional Western Medicine for 129 Patients of Heart Failure with Mid-range Ejection Fraction with Syndrome of Qi Deficiency and Blood Stasis：A Randomized Controlled Trial

The Effect of Shenqi Jianxin Formula （参芪健心方） on Cardiomyocyte Pyroptosis in Chronic Heart Failure Model Rats Based on the NLRP3/Caspase-1 Signaling Pathway

Related Author

XIE Peichi

LIU Pan

DING Zitong

BAI Jingyi

PANG Deqi

DAI Xiaohua

WANG Xianliang

ZHANG Jingyi

Related Institution

First Clinical Medical College，Anhui University of Chinese Medicine

College of Traditional Chinese Medicine，Anhui University of Chinese Medicine

The First Affiliated Hospital of Anhui University of Chinese Medicine

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine/ National Clinical Research Center for Chinese Medicine

Tianjin University of Traditional Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Effect of Shenfu Injection （参附注射液） on SIRT1 Deacetylation-modified Regulation of HMGB1/TLR4/NF-κB Pathway in Isoproterenol-induced Cardiomyocyte Injury Model

DOI：10.13288/j.11-2166/r.2024.14.012

摘要

Abstract

关键词

Keywords

references